No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OKYO OKYO Pharma
- 1.280
- -0.020-1.54%
Close Jun 18 16:00 ET
- 1.250
- -0.030-2.34%
Post 19:57 ET
42.54MMarket Cap-2461P/E (TTM)
1.380High1.260Low3.22KVolume1.380Open1.300Pre Close4.17KTurnover0.02%Turnover RatioLossP/E (Static)33.24MShares3.07052wk High-20.65P/B22.72MFloat Cap0.92052wk Low--Dividend TTM17.75MShs Float7.000Historical High--Div YieldTTM9.22%Amplitude0.920Historical Low1.294Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
OKYO Pharma Announces Participation in May 2024 Investor Conferences
London and New York, NY, May 8, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye d
OKYO Pharma to Include Additional Analyses in Upcoming Dry Eye Disease Key Opinion Leader Event | NASDAQ:OKYO
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024.
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye
Borr Drilling, Aehr Test Systems, Airship AI Among Premarket Losers' Pack
OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.
OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.
Comments
OKYO Pharma's OK-101: A Revolutionary Treatment for Dry Eye Disease.
Dry Eye Disease (DED) is a prevalent condition affecting millions globally, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. Despite the availability of various treatments, many patients continue to seek more effective solutions. In a significant development, OKYO Pharma has announced that its drug, OK-101, has achie...
Dry Eye Disease (DED) is a prevalent condition affecting millions globally, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. Despite the availability of various treatments, many patients continue to seek more effective solutions. In a significant development, OKYO Pharma has announced that its drug, OK-101, has achie...
$OKYO Pharma(OKYO.US$ HTB list! 60K LTB
$OKYO Pharma(OKYO.US$ OKYO Pharma Says OK-101 Achieves Statistical Significance For Multiple Signs And Symptoms Of Dry Eye Disease Including Ocular Pain Relief In Its First-in-Human Phase 2 Trial Of OK-101
$OKYO Pharma(OKYO.US$ SUPER BIG NEWS but no movement, what's the deal with this one?
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg